Hereditary Colorectal cancer syndromes and genetic testing

Journal of Surgical Oncology

Volumn 111, Issue 1, 2015, Pages 103-111

  Macaron, Carole ^a   Leach, Brandie H ^a   Burke, Carol A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Colon cancer; Genetic testing; Hereditary syndromes

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CLINICAL FEATURE; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GENETIC SCREENING; HEREDITARY COLORECTAL CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; JUVENILE POLYPOSIS SYNDROME; PEUTZ JEGHERS SYNDROME; POLYMERASE PROOFREADING ASSOCIATED POLYPOSIS; PTEN HAMARTOMA TUMOR SYNDROME; COLORECTAL NEOPLASMS; GENETICS; NEOPLASTIC SYNDROMES, HEREDITARY;

COLORECTAL NEOPLASMS; GENETIC TESTING; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY;

EID: 84920174166     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23706     Document Type: Article

References (81)

1. Burn J, Chapman P, Delhanty J, et al.: The UK northern region genetic register for familial adenomatous polyposis coli: Use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. J Med Genet 1991;28:289-296.
2. Jarvinen HJ: Epidemiology of familial adenomatous polyposis in finland: Impact of family screening on the colorectal cancer rate and survival. Gut 1992;33:357-360.
3. Bisgaard ML, Fenger K, Bulow S, et al.: Familial adenomatous polyposis (FAP): Frequency, penetrance, and mutation rate. Hum Mutat 1994;3:121-125.
4. Neklason DW, Stevens J, Boucher KM, et al.: American founder mutation for attenuated familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008;6:46-52.
5. Bianchi LK, Burke CA, Bennett AE, et al.: Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008;6:180-185.
6. Burke CA, Beck GJ, Church JM, et al.: The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999;49:358-364.
7. Bulow S, Alm T, Fausa O, et al.: Duodenal adenomatosis in familial adenomatous polyposis. DAF project group. Int J Colorectal Dis 1995;10:43-46.
8. Spigelman AD, Williams CB, Talbot IC, et al.: Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989;2:783-785.
9. Ruys AT, Alderlieste YA, Gouma DJ, et al.: Jejunal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2010;8:731-733.
10. Jarrar AM, Milas M, Mitchell J, et al.: Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011;253:515-521.
11. National comprehensive cancer network.genetic/familial high-risk assessment: Colorectal, version I. 2014. Updated 2014.
12. Grover S, Kastrinos F, Steyerberg EW, et al.: Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012;308:485-492.
13. Vasen HF, Moslein G, Alonso A, et al.: Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008;57:704-713.
14. Church J: Familial adenomatous polyposis. Surg Oncol Clin N Am 2009;18:585-598.
15. Bulow C, Vasen H, Jarvinen H, et al.: Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 2000;119:1454-1460.
16. Heiskanen I, Jarvinen HJ: Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Int J Colorectal Dis 1997;12:9-13.
17. Koskenvuo L, Renkonen-Sinisalo L, Jarvinen HJ, et al.: Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. Int J Colorectal Dis 2014;29:225-230.
18. van Duijvendijk P, Vasen HF, Bertario L, et al.: Cumulative risk of developing polyps or malignancy at the ileal pouch-anal anastomosis in patients with familial adenomatous polyposis. J Gastrointest Surg 1999;3:325-330.
19. Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
20. Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
21. Johnson MD, Mackey R, Brown N, et al.: Outcome based on management for duodenal adenomas: Sporadic versus familial disease. J Gastrointest Surg 2010;14:229-235.
22. Burke CA, Santisi J, Church J, et al.: The utility of capsule endoscopy small bowel surveillance in patients with polyposis. Am J Gastroenterol 2005;100:1498-1502.
23. Phillips RK, Wallace MH, Lynch PM, et al.: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-860.
24. Tenesa A, Campbell H, Barnetson R, et al.: Association of MUTYH and colorectal cancer. Br J Cancer 2006;95:239-242.
25. Al-Tassan N, Chmiel NH, Maynard J, et al.: Inherited variants of MYH associated with somatic G:C->T:A mutations in colorectal tumors. Nat Genet 2002;30:227-232.
26. Cleary SP, Cotterchio M, Jenkins MA, et al.: Germline MutY human homologue mutations and colorectal cancer: A multisite case-control study. Gastroenterology 2009;136:1251-1260.
27. Sieber OM, Lipton L, Crabtree M, et al.: Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-799.
28. Wang L, Baudhuin LM, Boardman LA, et al.: MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004;127:9-16.
29. Farrington SM, Tenesa A, Barnetson R, et al.: Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 2005;77:112-119.
30. Nielsen M, Joerink-van de Beld MC, Jones N, et al.: Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology 2009;136:471-476.
31. Theodoratou E, Campbell H, Tenesa A, et al.: A large-scale metaanalysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 2010;103:1875-1884.
32. Win AK, Dowty JG, Cleary SP, et al.: Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 2014;146:1208-1211.e5.
33. Boparai KS, Dekker E, Van Eeden S, et al.: Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 2008;135:2014-2018.
34. Vogt S, Jones N, Christian D, et al.: Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009;137:1976-1985.e1-e10.
35. Palles C, Cazier JB, Howarth KM, et al.: Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013;45:136-144.
36. Nagy R, Sweet K, Eng C: Highly penetrant hereditary cancer syndromes. Oncogene 2004;23:6445-6470.
37. Mccoll I, Busxey HJ, Veale AM, et al.: Juvenile polyposis coli. Proc R Soc Med 1964;57:896-897.
38. Burt RW, Bishop DT, Lynch HT, et al.: Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO collaborating centre for the prevention of colorectal cancer. Bull World Health Organ 1990;68:655-665.
39. Jass JR: Juvenile polyposis. In: Phillips RKS, Spigelman AD, Thompson JPS (eds). Familial Adenomatous Polyposis and Other Polyposis Syndromes. London: Edward Arnold, 1994:203.
40. Agnifili A, Verzaro R, Gola P, et al.: Juvenile polyposis: Case report and assessment of the neoplastic risk in 271 patients reported in the literature. Dig Surg 1999;16:161-166.
41. Merg A, Howe JR: Genetic conditions associated with intestinal juvenile polyps. Am J Med Genet C Semin Med Genet 2004;129C: 44-55.
42. Friedl W, Uhlhaas S, Schulmann K, et al.: Juvenile polyposis: Massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum Genet 2002; 111:108-111.
43. O'Malley M, LaGuardia L, Kalady MF, et al.: The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome. Dis Colon Rectum 2012;55:886-892.
44. Gallione CJ, Repetto GM, Legius E, et al.: A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363:852-859.
45. Howe JR, Sayed MG, Ahmed AF, et al.: The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 2004; 41:484-491.
46. Aretz S, Stienen D, Uhlhaas S, et al.: High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. J Med Genet 2007; 44:702-709.
47. van Hattem WA, Brosens LA, de Leng WW, et al.: Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis. Gut 2008;57:623-627.
48. Sweet K, Willis J, Zhou XP, et al.: Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005;294:2465-2473.
49. Oncel M, Church JM, Remzi FH, et al.: Colonic surgery in patients with juvenile polyposis syndrome: A case series. Dis Colon Rectum 2005;48:49-55discussion 55-56.
50. Hemminki A, Markie D, Tomlinson I, et al.: A serine/threonine kinase gene defective in peutz-jeghers syndrome. Nature 1998;391: 184-187.
51. Jenne DE, Reimann H, Nezu J, et al.: Peutz-jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38-43.
52. McGarrity TJ, Kulin HE, Zaino RJ: Peutz-jeghers syndrome. Am J Gastroenterol 2000;95:596-604.
53. Utsunomiya J, Gocho H, Miyanaga T, et al.: Peutz-jeghers syndrome: Its natural course and management. Johns Hopkins Med J 1975;136:71-82.
54. Giardiello FM, Brensinger JD, Tersmette AC, et al.: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-1453.
55. Aaltonen L, Jarvin H, Gruber S, et al.: Peutz Jeghers syndrome. In: Hamilton SR, Aaltonen LA (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. France: IARC Press. 2000:p 74.
56. Beggs AD, Latchford AR, Vasen HF, et al.: Peutz-Jeghers syndrome: A systematic review and recommendations for management. Gut 2010;59:975-986.
57. Oncel M, Remzi FH, Church JM, et al.: Benefits of 'clean sweep' in Peutz-Jeghers patients. Colorectal Dis 2004;6:332-335.
58. Mester J, Eng C: When overgrowth bumps into cancer: The PTENopathies. Am J Med Genet C Semin Med Genet 2013;163C:114-121.
59. Heald B, Mester J, Rybicki L, et al.: Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010;139:1927-1933.
60. Mester J, Eng C: Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med 2012;14:819-822.
61. Vasen HF, Mecklin JP, Khan PM, et al.: The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-425.
62. Vasen HF, Watson P, Mecklin JP, et al.: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456.
63. Umar A, Boland CR, Terdiman JP, et al.: Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96: 261-268.
64. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP working group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009;11:15-20.
65. Wijnen JT, Vasen HF, Khan PM, et al.: Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998;339:511-518.
66. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al.: Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 2013;144:926-932.e1quiz e13-e14.
67. Lindor NM, Rabe K, Petersen GM, et al.: Lower cancer incidence in amsterdam-I criteria families without mismatch repair deficiency: Familial colorectal cancer type X. JAMA 2005;293:1979-1985.
68. Bonadona V, Bonaiti B, Olschwang S, et al.: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in lynch syndrome. JAMA 2011;305:2304-2310.
69. Lee JS, Petrelli NJ, Rodriguez-Bigas MA: Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg 2001;181: 207-210.
70. Parry S, Win AK, Parry B, et al.: Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: The advantage of more extensive colon surgery. Gut 2011;60:950-957.
71. van der Post RS, Kiemeney LA, Ligtenberg MJ, et al.: Risk of urothelial bladder cancer in lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010;47: 464-470.
72. de Jong AE, Hendriks YM, Kleibeuker JH, et al.: Decrease in mortality in lynch syndrome families because of surveillance. Gastroenterology 2006;130:665-671.
73. Engel C, Rahner N, Schulmann K, et al.: Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2010;8: 174-182.
74. Rex DK, Johnson DA, Anderson JC, et al.: American college of gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-750.
75. Lindor NM, Petersen GM, Hadley DW, et al.: Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: A systematic review. JAMA 2006;296:1507-1517.
76. Kalady MF: Surgical management of hereditary nonpolyposis colorectal cancer. Adv Surg 2011;45:265-274.
77. Burn J, Gerdes AM, Macrae F, et al.: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet 2011;378: 2081-2087.
78. Manchanda R, Menon U, Michaelson-Cohen R, et al.: Hereditary non-polyposis colorectal cancer or lynch syndrome: The gynaecological perspective. Curr Opin Obstet Gynecol 2009;21:31-38.
79. Schmeler KM, Lynch HT, Chen LM, et al.: Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome. N Engl J Med 2006;354:261-269.
80. Lu KH, Dinh M, Kohlmann W, et al.: Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005;105:569-574.
81. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al.: A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: Meeting highlights and bethesda guidelines. J Natl Cancer Inst 1997;89:1758-1762.